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Aim: Anticonvulsant medications are frequently used in clinical practice to treat
psychiatric disorders in children and adolescents, but the evidence for their efficacy is
uncertain. We conducted a systematic review of published randomized controlled trials
(RCT) that assessed the psychiatric benefit of anticonvulsants in patients under 18 years
of age.
Method: The Medline, Scopus, Web of Science, and ClinicalTrials.gov databases were
systematically searched for peer-reviewed primary publications of RCTs with a minimum
of 10 patients per treatment arm through December 2017.
Results: Out of 355 identified non-duplicative publications, 24 met the inclusion criteria.
Most RCTs were to treat bipolar disorder (n= 12) or manage recurrent aggression (n= 9).
Few (n= 3) had both a multisite design and adequate statistical power. Valproate was the
most frequently studied anticonvulsant (n = 15). Out of three placebo-controlled RCTs of
valproate in bipolar disorder, none showed efficacy. In four RCTs, valproate was inferior to
the antipsychotic risperidone. In several small, single-site RCTs, valproate and sulthiame
were better than placebo for the management of recurrent aggression.
Conclusions: Currently available RCTs do not support the efficacy of anticonvulsants as
mood stabilizers in children. There is some preliminary evidence from small RCTs of the
efficacy of some anticonvulsants in the control of aggression and behavioral dyscontrol
in conduct disorder, autism, and intellectual disability.
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INTRODUCTION
Anticonvulsant medications have been used for decades in the treatment of psychiatric disorders. It
is postulated that the biochemical mechanisms underlying their anti-seizure activity can lead also
to stabilization of mood and behavior (1). In adults, valproate, carbamazepine, and lamotrigine
have demonstrated efficacy as mood stabilizers in acute mania and/or as maintenance treatment
of bipolar disorder to prevent recurrence (2–5). Oxcarbazepine and topiramate are also used, but
without clear-cut evidence of efficacy (6–8). In addition, some anticonvulsants have anti-aggressive
properties, and carbamazepine, oxcarbazepine, and phenytoin have been found to be effective in
the management of recurrent impulsive aggression (9).
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In children (here intended as individuals under 18 years
of age), anticonvulsants are frequently used to stabilize mood
and behavior, usually in the context of bipolar disorder or
other disorders that are accompanied by recurrent aggression,
self-injury, or severe temper dysregulation, such as intellectual
disability, autism spectrum disorder, conduct disorder, and
attention deficit-hyperactivity disorder (ADHD) (10). In fact,
anticonvulsants have been among the most commonly used
pharmacological agents in pediatric bipolar disorder (11).
No anticonvulsant currently carries regulatory approval for
pediatric use for the treatment of bipolar disorder or other
psychiatric indications. Thus, anticonvulsants are used “off
label” in children. Uncontrolled investigations have been indeed
suggestive of efficacy (12). Uncontrolled studies, however,
cannot constitute evidence of efficacy, especially in psychiatric
conditions, such as mood disorders, that are characterized by
high rates of spontaneous improvement and placebo effect. Only
randomized controlled trials (RCTs) can demonstrate efficacy.
In order to evaluate the evidence for the efficacy of
anticonvulsants in the treatment of psychiatric disorders in
children, we conducted a systematic review of RCTs. The main
aim was to identify which anticonvulsants, if any, have proven
efficacy in the treatment of psychiatric disorders in children.
According to evidence-based medicine standards, efficacy would
be proven if supported by at least two independent RCTs.
METHODS
The standard methodology of systematic reviews was applied
(13).
Selection Criteria
We searched for English language, peer-reviewed publications
that were the primary reports of RCTs testing the efficacy
of anticonvulsants in the treatment of psychiatric disorders
in children. Included were all anticonvulsants with proven
anticonvulsant effects and currently approved for the treatment
of epilepsy. The psychiatric conditions included: mood
disorders (depression and bipolar disorder), conduct disorder,
recurrent aggression, ADHD, anxiety, autism spectrum disorder,
eating disorders, and tic disorders. Excluded was the use
of anticonvulsants for migraine, headache, neuropathy, or
pain management. Excluded were also RCTs in which the
anticonvulsant was not the independent variable being tested
for efficacy. A minimum sample size of 10 children randomized
to each treatment group was required for inclusion. RCTs that
enrolled adults, in addition to children, were included only if the
study sample had a preponderance of subjects under 18 years of
age.
Search Mechanism
The Medline, Web of Science, and Scopus databases were
systematically searched for English language publications
throughDecember 2017. The search inputs were: “anticonvulsant
and children (age 0–17 years) and psychiatric disorder or bipolar
disorder or mania or depression or anxiety or aggression or
autism or conduct disorder or ADHD or Tourette or eating
disorder,” repeated for specific anticonvulsant medication
(i.e., valproate, carbamazepine, oxcarbazepine, lamotrigine,
phenytoin, topiramate, gabapentin, pregabalin, levetiracetam,
clonazepam, clobazam, perampanel). All searches used clinical
trial as a filter. In addition, the ClinicalTrial.gov database was
similarly searched for clinical trials of anticonvulsants in children
for bipolar disorder, anxiety, ADHD, and autism.
Review and Selection Process
After removal of duplicates, the publication titles and abstracts
were visually inspected and reviewed independently based on the
selection criteria by two experts (CD and BV). Disagreements
were discussed and resolved by consensus in order to arrive at
an agreed upon list of RCT publications.
Analysis
A qualitative analysis of the selected studies was independently
conducted, based on the study reported characteristics and
outcomes. The characteristics, quality, and limitations of each
selected RCT were assessed based on the published report.
Disagreements between raters were resolved by discussion
and consensus. When additional information was needed,
the corresponding author of the report was contacted in an
attempt to acquire additional information. In assessing quality
of each study, the presence of the following seven elements
was examined: (1) double-blind design; (2) description of
randomization and masking methods to minimize assessment
biases; (3) multiple clinical sites (more than one); (4) sample size
of at least 40 children randomized to each treatment group to
provide statistical power to detect medium treatment effect sizes;
(5) sufficient exposure to treatment with respect to dosage (i.e.,
dose in the known therapeutic range for anticonvulsant action,
supported by plasma levels when available) and duration of
treatment (at least 3 weeks for acute efficacy and at least 12 weeks
for efficacy of maintenance treatment); (6) acceptable sample
retention (<25% of the randomized sample lost to follow-up);
and (7) intent-to-treat analyses.
RESULTS
The initial search yielded a total of 351 non-duplicate
publications; an additional 4 publications were identified
through manual reference review or other sources. Of these
355 publications, 331 were excluded as not meeting the pre-
specified selection criteria, being 9 not in English, 11 not on
anticonvulsants, 136 not for psychiatric use, 162 not RCT, 2 with
too small of a sample size, and 11 secondary analyses of RCT (see
Figure 1).
A total of 24 publications, each constituting the primary report
of a RCT of anticonvulsant efficacy in psychiatric disorder in
children were identified (see Tables 1, 2). Half of these RCTs
were in the treatment of bipolar disorder, including acute control
of manic/mixed episodes and chronic maintenance to prevent
recurrence (see Table 3). The other most common psychiatric
use was for the control of recurrent impulsive aggression, mainly
in the context of a neurodevelopmental disorder, such as autism
and/or intellectual disability (n= 9).
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FIGURE 1 | Review flowchart.
The RCTs were conducted in double-blind conditions, except
for four, which, however, employed masking methods (i.e.,
blinded raters) to limit ascertainment biases. Most were placebo-
controlled, while four were comparative effectiveness RCTs of
different active medications without a placebo control. The age
of the RCT samples was mainly between 5 and 17 years. Only two
RCTs included preschoolers as young as 3 years of age (21, 32).
Treatment exposure, with respect to adequate dosage and
sufficient duration, as well as retention and statistical analyses,
were considered to be satisfactory, but only five RCT involved
more than one site and only five had a sample size of at least 40
subjects per treatment group (see Supplementary Table 1). Of the
24 RCTs, 13 (54%) did not find a statistically significant difference
(Tables 1, 2).
Only two RCTs were deemed to have met all the specified
seven quality elements (17, 24), and, in particular, to have
adequate sample size. Neither of these studies found the
anticonvulsant medication to be better than placebo.
Most of the RCTs evaluated valproate (n = 15), while
three tested carbamazepine (one of these studies included also
valproate). The remaining anticonvulsants (oxcarbazepine,
lamotrigine, levetiracetam, clonazepam, topiramate, and
sulthiame) had only one or two RCTs each. Valproate was tested
as a mood stabilizer in bipolar disorder in 10 RCTs and in the
prevention of recurrent aggression in five RCTs. In bipolar
disorder, none of the three placebo-controlled RCTs showed
efficacy (16, 17, 21). Four RCTs showed superiority of the
antipsychotic risperidone over valproate (18–21). No difference
was detected between valproate and lithium (14), carbamazepine
(23), or quetiapine (15). Finally, one RCT conducted to test the
antimanic effects of topiramate in hospitalized youths, using
valproate as a comparison group, found valproate to be superior
to topiramate (22).
As anti-aggressive agent, valproate showed no difference from
placebo in one RCT (29) and was better than placebo in three
small RCTs, one in children with autism spectrum disorder (30)
and two in children with conduct disorder or ADHD (26, 28).
One RCT that compared high with low dose of valproate found
superiority of the higher dose (27).
Four RCTs tested carbamazepine or oxcarbazepine in the
treatment of mania, aggression, or ADHD. Two of these RCTs
found no difference from placebo (24, 31). Another RCT found
carbamazepine inferior to clonidine in ADHD (32), and in the
third one there was no difference vs. valproate (23).
No evidence of efficacy emerged for lamotrigine,
levetiracetam, and clonazepam. In two RCTs that were conducted
more than 40 years ago in institutionalized, severely impaired
subjects with intellectual disability, including both youths
and adults, sulthiame, was better than placebo for controlling
aggression and hyperactivity (36, 37).
Conclusions
This systematic review identified mostly small controlled studies
with important methodological limitations and heterogeneity
with respect to type of medication and clinical target. No
evidence emerged for the efficacy of anticonvulsants in children
with bipolar disorder. There is limited evidence for the efficacy
of valproate and sulthiame for the management of aggressive
behavior. For sulthiame studies were conducted in samples that
included adult patients and the specific efficacy in children
cannot be estimated.
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.
DISCUSSION
To evaluate the evidence for efficacy of anticonvulsant
medications in psychiatric disorders of childhood, we conducted
a systematic qualitative review of relevant published RCTs.
We restricted the search to RCTs because uncontrolled studies
cannot provide evidence of treatment effects given the variable
placebo-response in psychiatric conditions.
Twenty-four RCTs met the pre-specified selection criteria
(Tables 1, 2). The medication dosage and the duration of
treatment were generally appropriate, and many studies
measured medication serum levels. Most of these RCTs,
however, had important methodological limitations, especially
a small sample size (<40 per treatment group), and therefore
inadequate statistical power to detect medium effect sizes (see
Supplementary Table 1).
A sample size of 40 subjects per treatment group will
provide 80% statistical power to detect a between-group effect
size usually considered in the medium range (e.g., a Cohen’s
d = 0.6) as statistically significant at a p ≤ 0.05 (38).
The small sample size of the large majority of these RCTs
strongly limits their capacity to identify statistically significant
treatment differences. In fact, out of 24 RCTs, 13 (54%) did not
find a statistically significant difference between the treatment
groups.
A considerable number of RCTs was conducted on valproate
(n = 15), three of which had adequate sample size, while few
studies were devoted to other anticonvulsants. In the treatment of
children with bipolar disorder, valproate showed no evidence of
superiority over placebo, and was actually inferior to risperidone
based on four RCT (Table 1).
Two RCTs compared valproate to lithium or quetiapine,
respectively, in bipolar disorder, and found no difference between
treatment groups (14, 15). Considering the small sample size
of these RCTs and the lack of a placebo condition, the lack
of difference cannot be interpreted as evidence of efficacy.
Another, single-site, RCT compared topiramate to valproate in
hospitalized, acutely manic youths (22). This study, which had
been designed to test the efficacy of topiramate, found valproate
to be superior to topiramate. The report, however, lacks an
adequate description of the masking methods, and the especially
large effect size is surprising and possibly due to the specific
context of the hospital where the study was conducted.
These data on anticonvulsants in child bipolar disorder
appear to be at odds with the evidence for efficacy of
valproate, carbamazepine, and lamotrigine in adults with bipolar
disorder. In adults, valproate and carbamazepine are superior
to placebo in acute mania (2, 3), although less effective than
antipsychotics (3), and lamotrigine is superior to placebo in
bipolar depression (4). More limited evidence supports also the
efficacy of valproate as maintenance treatment in adult bipolar
disorder (5). The discrepancy between adults and children is
suggestive of developmental differences in the psychopathology
of the mood dysregulation. It should also be pointed out that
there are several psychiatric medications, such as antidepressants
and benzodiazepines, whose efficacy has been shown in adults but
not in children (39).
Frontiers in Psychiatry | www.frontiersin.org 5 June 2018 | Volume 9 | Article 270
Davico et al. Psychiatric Use of Anticonvulsants in Children
T
A
B
L
E
2
|
R
a
n
d
o
m
iz
e
d
c
o
n
tr
o
lle
d
c
lin
ic
a
lt
ria
ls
a
ss
e
ss
in
g
th
e
e
ffi
c
a
c
y
o
f
a
n
tic
o
n
vu
ls
a
n
t
m
e
d
ic
a
tio
n
s
in
th
e
tr
e
a
tm
e
n
t
o
f
c
h
ild
re
n
(u
n
d
e
r
1
8
ye
a
rs
o
f
a
g
e
)
w
ith
p
sy
c
h
ia
tr
ic
d
is
o
rd
e
rs
o
th
e
r
th
a
n
b
ip
o
la
r
d
is
o
rd
e
r
(n
=
1
2
)a
.
M
e
d
ic
a
ti
o
n
s
P
s
y
c
h
ia
tr
ic
d
is
o
rd
e
r
Ta
rg
e
t
D
e
s
ig
n
S
a
m
p
le
O
u
tc
o
m
e
m
e
a
s
u
re
s
D
o
s
a
g
e
/s
e
ru
m
le
v
e
l
R
e
s
u
lt
s
b
R
e
fe
re
n
c
e
s
V
a
lp
ro
a
te
O
D
D
o
r
C
D
E
xp
lo
si
ve
te
m
p
e
r,
m
o
o
d
la
b
ili
ty
,
a
g
g
re
ss
io
n
R
a
n
d
o
m
iz
a
tio
n
to
D
V
P
X
o
r
p
la
c
e
b
o
fo
r
6
w
e
e
ks
(p
h
a
se
1
)
fo
llo
w
e
d
b
y
c
ro
ss
-o
ve
r
to
o
th
e
r
tr
e
a
tm
e
n
t
fo
r
6
w
e
e
ks
(p
h
a
se
2
)
n
=
2
0
a
g
e
:
1
0
–1
8
y
M
o
d
ifi
e
d
O
ve
rt
A
g
g
re
ss
io
n
S
c
a
le
D
V
P
X
:
7
5
0
-1
,5
0
0
m
g
/d
D
V
P
X
su
p
e
rio
r
to
p
la
c
e
b
o
in
p
h
a
se
1
.
N
o
d
iff
e
re
n
c
e
in
p
h
a
se
2
D
o
n
o
va
n
e
t
a
l.
( 2
6
)
V
a
lp
ro
a
te
C
D
E
xp
lo
si
ve
te
m
p
e
r,
m
o
o
d
la
b
ili
ty
,
a
g
g
re
ss
io
n
R
a
n
d
o
m
iz
a
tio
n
to
lo
w
o
r
h
ig
h
d
o
se
o
f
va
lp
ro
a
te
fo
r
7
w
e
e
ks
n
=
7
1
a
g
e
:
1
6
y
(m
e
a
n
)
C
G
I-
S
C
G
I-
I
L
o
w
d
o
se
:
u
p
to
2
5
0
m
g
/d
H
ig
h
d
o
se
:
5
0
0
-1
,5
0
0
m
g
/d
H
ig
h
d
o
se
o
f
va
lp
ro
a
te
su
p
e
rio
r
to
lo
w
e
r
d
o
se
S
te
in
e
r
e
t
a
l.
( 2
7
)
V
a
lp
ro
a
te
A
D
H
D
w
ith
O
D
D
o
r
C
D
A
g
g
re
ss
io
n
In
iti
a
lt
re
a
tm
e
n
t
w
ith
st
im
u
la
n
t
m
o
n
o
th
e
ra
p
y,
fo
llo
w
e
d
b
y
ra
n
d
o
m
iz
a
tio
n
to
D
V
P
X
o
r
p
la
c
e
b
o
fo
r
8
w
e
e
ks
n
=
3
0
a
g
e
:
6
–1
3
y
R
e
tr
o
sp
e
c
tiv
e
-M
o
d
ifi
e
d
O
ve
rt
A
g
g
re
ss
io
n
S
c
a
le
2
0
m
g
/k
g
/d
.
V
a
lp
ro
ic
a
c
id
se
ru
m
le
ve
l:
6
8
.1
m
c
g
/m
L
(m
e
a
n
)
D
V
P
X
su
p
e
rio
r
to
p
la
c
e
b
o
B
la
d
e
r
e
t
a
l.
(2
8
)
V
a
lp
ro
a
te
A
u
tis
m
sp
e
c
tr
u
m
d
is
o
rd
e
r
A
g
g
re
ss
io
n
R
a
n
d
o
m
iz
a
tio
n
to
va
lp
ro
a
te
o
r
p
la
c
e
b
o
fo
r
8
w
e
e
ks
n
=
3
0
a
g
e
:
6
–2
0
y
A
B
C
C
G
I-
I
V
a
lp
ro
ic
a
c
id
se
ru
m
le
ve
l:
7
7
.8
m
c
g
/m
L
(m
e
a
n
)
N
o
d
iff
e
re
n
c
e
b
e
tw
e
e
n
va
lp
ro
a
te
a
n
d
p
la
c
e
b
o
H
e
lli
n
g
s
e
t
a
l.
( 2
9
)
V
a
lp
ro
a
te
A
u
tis
m
sp
e
c
tr
u
m
d
is
o
rd
e
r
Ir
rit
a
b
ili
ty
/
A
g
g
re
ss
io
n
R
a
n
d
o
m
iz
a
tio
n
to
D
V
P
X
o
r
p
la
c
e
b
o
fo
r
1
2
w
e
e
ks
n
=
2
7
a
g
e
:
5
–1
7
y
A
B
C
C
G
I-
I
D
V
P
X
:
u
p
to
1
,0
0
0
m
g
/d
D
V
P
X
su
p
e
rio
r
to
p
la
c
e
b
o
H
o
lla
n
d
e
r
e
t
a
l.
(3
0
)
C
a
rb
a
m
a
ze
p
in
e
C
D
A
g
g
re
ss
io
n
R
a
n
d
o
m
iz
a
tio
n
to
c
a
rb
a
m
a
ze
p
in
e
o
r
p
la
c
e
b
o
fo
r
6
w
e
e
ks
n
=
2
2
a
g
e
:
5
–1
2
y
O
ve
rt
A
g
g
re
ss
io
n
S
c
a
le
,
C
G
I,
C
h
ild
re
n
’s
P
sy
c
h
ia
tr
ic
R
a
tin
g
S
c
a
le
2
0
0
–8
0
0
m
g
/d
(m
e
a
n
6
8
3
)
S
e
ru
m
c
a
rb
a
m
a
ze
p
in
e
le
ve
ls
:
5
.0
-9
.1
m
c
g
/m
L
N
o
d
iff
e
re
n
c
e
b
e
tw
e
e
n
c
a
rb
a
m
a
ze
p
in
e
a
n
d
p
la
c
e
b
o
C
u
e
va
e
t
a
l.
(3
1
)
C
a
rb
a
m
a
ze
p
in
e
A
D
H
D
A
D
H
D
sy
m
p
to
m
s
R
a
n
d
o
m
iz
a
tio
n
to
c
a
rb
a
m
a
ze
p
in
e
o
r
c
lo
n
id
in
e
fo
r
4
w
e
e
ks
n
=
5
0
a
g
e
:
4
–1
2
y
V
a
n
d
e
rb
ilt
A
D
H
D
R
a
tin
g
S
c
a
le
U
n
sp
e
c
ifi
e
d
C
lo
n
id
in
e
su
p
e
rio
r
to
c
a
rb
a
m
a
ze
p
in
e
N
a
ir
a
n
d
M
a
h
a
d
e
va
n
,
( 3
2
)
L
e
ve
tir
a
c
e
ta
m
To
u
re
tt
e
d
is
o
rd
e
r
T
ic
s
W
ith
in
-s
u
b
je
c
t,
c
ro
ss
o
ve
r
w
ith
ra
n
d
o
m
iz
a
tio
n
to
le
ve
tir
a
c
e
ta
m
o
r
p
la
c
e
b
o
,
se
q
u
e
n
tia
lly
,
fo
r
4
w
e
e
ks
e
a
c
h
n
=
2
2
a
g
e
:
8
–1
6
y
Y
a
le
G
lo
b
a
lT
ic
S
e
ve
rit
y
S
c
a
le
U
p
to
3
0
m
g
/k
g
/d
N
o
d
iff
e
re
n
c
e
b
e
tw
e
e
n
le
ve
tir
a
c
e
ta
m
a
n
d
p
la
c
e
b
o
S
m
ith
-H
ic
ks
e
t
a
l.
( 3
3
)
L
e
ve
tir
a
c
e
ta
m
A
u
tis
m
sp
e
c
tr
u
m
d
is
o
rd
e
r
H
yp
e
ra
c
tiv
ity
,
im
p
u
ls
iv
ity
,a
g
g
re
ss
io
n
,
a
n
d
m
o
o
d
la
b
ili
ty
R
a
n
d
o
m
iz
a
tio
n
to
le
ve
tir
a
c
e
ta
m
o
r
p
la
c
e
b
o
fo
r
1
0
w
e
e
ks
n
=
2
0
a
g
e
:5
–1
7
y
C
G
I-
I,
A
B
C
,
C
o
n
n
e
rs
’
R
a
tin
g
S
c
a
le
-R
e
vi
se
d
8
6
3
m
g
/d
(m
e
a
n
)
N
o
d
iff
e
re
n
c
e
b
e
tw
e
e
n
le
ve
tir
a
c
e
ta
m
a
n
d
p
la
c
e
b
o
W
a
ss
e
rm
a
n
e
t
a
l.
( 3
4
)
C
lo
n
a
ze
p
a
m
A
n
xi
e
ty
d
is
o
rd
e
rs
D
e
c
re
a
se
in
a
n
xi
e
ty
sy
m
p
to
m
s
W
ith
in
-s
u
b
je
c
t,
c
ro
ss
o
ve
r
w
ith
ra
n
d
o
m
iz
a
tio
n
to
c
lo
n
a
ze
p
a
m
o
r
p
la
c
e
b
o
,
se
q
u
e
n
tia
lly
,
e
a
c
h
fo
r
4
w
e
e
ks
n
=
1
5
a
g
e
:
7
–1
3
y
C
h
ild
re
n
M
a
n
ife
st
A
n
xi
e
ty
S
c
a
le
U
p
to
2
m
g
/d
N
o
d
iff
e
re
n
c
e
b
e
tw
e
e
n
c
lo
n
a
ze
p
a
m
a
n
d
p
la
c
e
b
o
G
ra
a
e
e
t
a
l.
( 3
5
)
S
u
lth
ia
m
e
In
te
lle
c
tu
a
l
d
is
a
b
ili
ty
H
yp
e
ra
c
tiv
ity
,
a
g
g
re
ss
io
n
W
ith
in
-s
u
b
je
c
t,
c
ro
ss
o
ve
r
w
ith
ra
n
d
o
m
iz
a
tio
n
to
su
lth
ia
m
e
o
r
p
la
c
e
b
o
,
se
q
u
e
n
tia
lly
,
e
a
c
h
fo
r
6
w
e
e
ks
n
=
4
2
a
g
e
:7
–3
8
y
(m
e
a
n
1
7
)
B
e
h
a
vi
o
r
ra
tin
g
sc
a
le
U
p
to
6
0
0
m
g
/d
S
u
lth
ia
m
e
su
p
e
rio
r
to
p
la
c
e
b
o
M
o
ff
a
t
e
t
a
l.
( 3
6
)
S
u
lth
ia
m
e
In
te
lle
c
tu
a
l
d
is
a
b
ili
ty
H
yp
e
ra
c
tiv
ity
,
a
g
g
re
ss
io
n
R
a
n
d
o
m
iz
a
tio
n
to
su
lth
ia
m
e
o
r
p
la
c
e
b
o
fo
r
1
4
w
e
e
ks
n
=
3
4
a
g
e
:
6
–2
4
y
B
e
h
a
vi
o
r
ra
tin
g
sc
a
le
U
p
to
1
5
m
g
/k
g
/d
S
u
lth
ia
m
e
su
p
e
rio
r
to
p
la
c
e
b
o
A
l-
K
a
is
ia
n
d
M
c
G
u
ire
,
( 3
7
)
a
D
o
u
b
le
-b
lin
d
m
a
s
ki
n
g
u
n
le
s
s
o
th
e
rw
is
e
s
p
e
c
ifi
e
d
.
b
S
ta
ti
s
ti
c
a
lly
s
ig
n
ifi
c
a
n
t
d
iff
e
re
n
c
e
s
a
t
p
≤
0
.0
5
.
A
B
C
,
A
b
e
rr
a
n
t
B
e
h
a
vi
o
r
C
h
e
c
kl
is
t;
A
D
H
D
,
a
tt
e
n
ti
o
n
d
e
fic
it
/h
yp
e
ra
c
ti
vi
ty
d
is
o
rd
e
r;
C
D
,
c
o
n
d
u
c
t
d
is
o
rd
e
r;
O
D
D
,
o
p
p
o
s
it
io
n
a
ld
e
fia
n
t
d
is
o
rd
e
r.
Frontiers in Psychiatry | www.frontiersin.org 6 June 2018 | Volume 9 | Article 270
Davico et al. Psychiatric Use of Anticonvulsants in Children
TABLE 3 | Primary target of the 24 randomized controlled clinical trials (RCTs) of
anticonvulsant medications in psychiatric disorders in children (under 18 years of
age).
no of RCTs
Control of acute symptoms of mania and irritability in bipolar disorder 9
Prevention of recurrent explosive aggression 9
Prevention of recurrence of bipolar acute episode 3
Control of symptoms of ADHD 1
Control of tics in tourette disorder 1
Control of symptoms of anxiety 1
For the management of aggression and explosive temper,
valproate showed efficacy in four small and single-site RCTs in
children with conduct disorder, ADHD, or autism (26–28, 30).
One of these, used valproate as add-on treatment to stimulant
medication in ADHD (28). Another one was designed as a
crossover trial, but could not complete the second segment of
the study and analyzed only the first part (26). Even if none of
these studies met all the methodological quality criteria, these
data can be taken as tentative evidence of efficacy of valproate
in controlling aggressive behavior. This is consistent with the
results of a meta-analysis of anticonvulsants in the management
of aggression in adults (9). These findings, however, should be
confirmed by adequately powered, multisite RCTs.
Little evidence of efficacy in bipolar disorder emerged
from the RCTs of other commonly used anticonvulsants. In
particular, a statistically powered, multi-site, placebo-controlled
trial of oxcarbazepine in bipolar disorder found no statistically
significant difference (24). Lamotrigine, which is effective in
bipolar depression in adults, did no better than placebo in a
RCT that included children aged from 10 to 17 years, although
secondary analyses found superiority in the 13- to 17-year-old
subgroup (26). Sulthiame, an infrequently used anticonvulsant,
was found better than placebo in 2 RCTs conducted more than
40 years ago for the control of aggression and hyperactivity in
institutionalized patients, including both youths and adults, with
severe intellectual disability (36, 37), but the implications of these
data for current practice are unclear.
The limitations of this review are primarily related to the
design characteristics of the studies and especially to the small
sample size of most of them. The studies are also rather
heterogeneous with respect to both the type of anticonvulsant
being tested and the clinical indication being targeted. Another
limitation is the relatively wide range of patient age in most
studies, some of which included also adults.
Based on the current data, the psychiatric use of
anticonvulsants in children cannot be supported according
to evidence-based standards. Their potential benefit valproate
and sulthiame for the management of recurrent aggression,
however, cannot be discounted. The potential benefit of these
medications must be in any case balanced against the risk for
adverse effects, including psychiatric ones (40).
In conclusion, the efficacy of anticonvulsants as mood
stabilizers in children with bipolar disorder remains unproven.
There is limited evidence that some anticonvulsantsmay decrease
aggressive behavior and explosive temper, especially in patients
with neurodevelopmental disorders and intellectual disability.
Because this evidence comes mainly from small studies, it
might be informative to conduct more precisely designed and
adequately powered RCT targeting recurrent and impulsive
aggression in children with neurodevelopmental disorders.
AUTHOR CONTRIBUTIONS
BV and CD were responsible for review, data extraction, and
evaluation. CC, RV, and MG contributed expert review and
helped in the data interpretation and manuscript preparation.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fpsyt.
2018.00270/full#supplementary-material
REFERENCES
1. Gobbi G, Janiri L. Sodium- and magnesium-valproate in vivo modulate
glutamatergic and GABAergic synapses in the medial prefrontal cortex.
Psychopharmacology (2006) 185:255–62. doi: 10.1007/s00213-006-0317-3
2. Macritchie K, Geddes JR, Scott J, HaslamD, de LimaM, Goodwin G. Valproate
for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev.
(2003) CD004052. doi: 10.1002/14651858.CD004052
3. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et
al. Comparative efficacy and acceptability of antimanic drugs in acute
mania: a multiple-treatments meta-analysis. Lancet (2011) 378:1306–15.
doi: 10.1016/S0140-6736(11)60873-8
4. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar
depression: independent meta-analysis and meta-regression of individual
patient data from five randomised trials. Br J Psychiatry (2009) 194:4–9.
doi: 10.1192/bjp.bp.107.048504
5. Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic
acid, valproate and divalproex in the maintenance treatment of
bipolar disorder. Cochrane Database Syst Rev. (2013) CD003196.
doi: 10.1002/14651858.CD003196.pub2
6. Pigott K, Galizia I, Vasudev K, Watson S, Geddes J, Young AH. Topiramate
for acute affective episodes in bipolar disorder in adults. Cochrane Database
Syst Rev. (2016) CD003384. doi: 10.1002/14651858.CD003384.pub3
7. Vasudev A, Macritchie K, Watson S, Geddes JR, Young AH. Oxcarbazepine in
the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev.
(2008) CD005171. doi: 10.1002/14651858.CD005171.pub2
8. Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH.
Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane
Database Syst Rev. (2001) CD004857. doi: 10.1002/14651858.CD004857.pub2
9. Jones RM, Arlidge J, Gillham R, Reagu S, van den Bree M, Taylor PJ.
Efficacy of mood stabilisers in the treatment of impulsive or repetitive
aggression: systematic review and meta-analysis. Br J Psychiatry (2011)
198:93–8. doi: 10.1192/bjp.bp.110.083030
10. Lopez-Larson M, Frazier JA. Empirical evidence for the use of lithium and
anticonvulsants in children with psychiatric disorders. Harv Rev Psychiatry
(2006) 14:285–304. doi: 10.1080/10673220601082869
Frontiers in Psychiatry | www.frontiersin.org 7 June 2018 | Volume 9 | Article 270
Davico et al. Psychiatric Use of Anticonvulsants in Children
11. Bhangoo RK, Lowe CH, Myers FS, Treland J, Curran J, Towbin KE, et
al. Medication use in children and adolescents treated in the community
for bipolar disorder. J Child Adolesc Psychopharmacol. (2003) 13:515–22.
doi: 10.1089/104454603322724904
12. Wagner KD, Weller EB, Carlson GA, Sachs G, Biederman J, Frazier JA,
et al. An open-label trial of divalproex in children and adolescents with
bipolar disorder. J Am Acad Child Adolesc Psychiatry (2002) 41:1224–30.
doi: 10.1097/00004583-200210000-00012
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al.
The PRISMA statement for reporting systematic reviews andmeta-analyses of
studies that evaluate health care interventions: explanation and elaboration.
PLoS Med. (2009) 6:e1000100. doi: 10.1371/journal.pmed.1000100
14. Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL,
Reed MD, et al. Double-blind 18-month trial of lithium versus divalproex
maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc
Psychiatry (2005) 44:409–17. doi: 10.1097/01.chi.0000155981.83865.ea
15. DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman
DH, et al. A double-blind randomized pilot study comparing quetiapine and
divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry (2006)
45:305–13. doi: 10.1097/01.chi.0000194567.63289.97
16. Findling RL, Frazier TW, Youngstrom EA, McNamara NK, Stansbrey RJ,
Gracious BL, et al. Double-blind, placebo-controlled trial of divalproex
monotherapy in the treatment of symptomatic youth at high risk
for developing bipolar disorder. J Clin Psychiatry (2007) 68:781–8.
doi: 10.4088/JCP.v68n0519
17. Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K,
et al. A double-blind, randomized, placebo-controlled trial of divalproex
extended-release in the treatment of bipolar disorder in children and
adolescents. J Am Acad Child Adolesc Psychiatry (2009) 48:519–32.
doi: 10.1097/CHI.0b013e31819c55ec
18. Pavuluri MN, Henry DB, Findling RL, Parnes S, Carbray JA, Mohammed
T, et al. Double-blind randomized trial of risperidone versus divalproex
in pediatric bipolar disorder. Bipolar Disord. (2010) 12:593–605.
doi: 10.1111/j.1399-5618.2010.00850.x
19. Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, et
al. A randomized controlled trial of risperidone, lithium, or divalproex
sodium for initial treatment of bipolar I disorder, manic or mixed
phase, in children and adolescents. Arch Gen Psychiatry (2012) 69:515–28.
doi: 10.1001/archgenpsychiatry.2011.1508
20. Walkup JT, Wagner KD, Miller L, Yenokyan G, Luby JL, Joshi PT, et al.
Treatment of early-age mania: outcomes for partial and nonresponders to
initial treatment. J Am Acad Child Adolesc Psychiatry (2015) 54:1008–19.
doi: 10.1016/j.jaac.2015.09.015
21. Kowatch RA, Scheffer RE,Monroe E, Delgado S, AltayeM, Lagory D. Placebo-
controlled trial of valproic acid versus risperidone in children 3-7 years of age
with bipolar I disorder. J Child Adolesc Psychopharmacol. (2015) 25:306–13.
doi: 10.1089/cap.2014.0166
22. Hebrani P, Behdani F, Manteghi AA. Double-blind, randomized, clinical trial
of topiramate versus sodium valproate for the treatment of bipolar disorder in
adolescents. Pak J Med Sci. (2009) 25:247–52.
23. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, et al.
Effect size of lithium, divalproex sodium, and carbamazepine in children and
adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry (2000)
39:713–20. doi: 10.1097/00004583-200006000-00009
24. Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, et
al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in
the treatment of bipolar disorder in children and adolescents. Am J Psychiatry
(2006)163:1179–86. doi: 10.1176/ajp.2006.163.7.1179
25. Findling RL, Chang K, Robb A, Foster VJ, Horrigan J, Krishen A, et
al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a
placebo-controlled, randomized withdrawal study. J Am Acad Child Adolesc
Psychiatry (2015) 54:1020–31. doi: 10.1016/j.jaac.2015.09.017
26. Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel W, et
al. Divalproex treatment for youth with explosive temper and mood lability:
a double-blind, placebo-controlled crossover design. Am J Psychiatry (2000)
157:818–20. doi: 10.1176/appi.ajp.157.5.818
27. Steiner H, Petersen ML, Saxena K, Ford S, Matthews Z. Divalproex sodium
for the treatment of conduct disorder: a randomized controlled clinical trial. J
Clin Psychiatry (2003) 64:1183–91. doi: 10.4088/JCP.v64n1007
28. Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V. Adjunctive
divalproex versus placebo for children with ADHD and aggression
refractory to stimulant monotherapy. Am J Psychiatry (2009) 166:1392–401.
doi: 10.1176/appi.ajp.2009.09020233
29. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, et al.
A double-blind, placebo-controlled study of valproate for aggression in youth
with pervasive developmental disorders. J Child Adolesc Psychopharmacol.
(2005) 15:682–92. doi: 10.1089/cap.2005.15.682
30. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et
al. Divalproex sodium vs placebo for the treatment of irritability in children
and adolescents with autism spectrum disorders. Neuropsychopharmacology
(2010) 35:990–8. doi: 10.1038/npp.2009.202
31. Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M.
Carbamazepine in aggressive children with conduct disorder: a double-blind
and placebo-controlled study. J Am Acad Child Adolesc Psychiatry (1996)
35:480–90. doi: 10.1097/00004583-199604000-00014
32. Nair V, Mahadevan S. Randomised controlled study-efficacy of clonidine
versus carbamazepine in children with ADHD. J Trop Pediatr. (2009) 55:116–
21. doi: 10.1093/tropej/fmn117
33. Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS. A double blind
randomized placebo control trial of levetiracetam in Tourette syndrome.Mov
Disord. (2007) 22:1764–70. doi: 10.1002/mds.21615
34. Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou
E, et al. Levetiracetam versus placebo in childhood and adolescent autism:
a double-blind placebo-controlled study. Int Clin Psychopharmacol. (2006)
21:363–7. doi: 10.1097/01.yic.0000224787.13782.0f
35. Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood
anxiety disorders. J Am Acad Child Adolesc Psychiatry (1994) 33:372–6.
doi: 10.1097/00004583-199403000-00011
36. Moffatt WR, Siddiqui AR, MacKay DN. The use of sulthiame with
disturbed mentally subnormal patients. Br J Psychiatry (1970) 117:673–8.
doi: 10.1192/bjp.117.541.673
37. Al Kaisi AH, McGuire RJ. The effect of sulthiame on disturbed behaviour
in mentally subnormal patients. Br J Psychiatry (1974) 124:45–9.
doi: 10.1192/bjp.124.1.45
38. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ:
Lawrence Erlbaum Associates (1988).
39. Vitiello B, Ordó-ez AE. Pharmacological treatment of children and
adolescents with depression. Expert Opin Pharmacother. (2016) 17:2273–9.
doi: 10.1080/14656566.2016.1244530
40. Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, et al. Epilepsy,
antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev.
(2016) 68:563–602. doi: 10.1124/pr.115.012021
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Davico, Canavese, Vittorini, Gandione and Vitiello. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Psychiatry | www.frontiersin.org 8 June 2018 | Volume 9 | Article 270
